Related Experiment Video

Updated: Jul 9, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

SERENA-6 and the regulatory limits of radiologic progression in modern oncology

Saeed Rafii1,2, Humaid O Al-Shamsi3,4,5,6, Adam Brufsky7

  • 1Department of Oncology, Mediclinic City Hospital, Dubai, United Arab Emirates. saeed.rafii@mediclinic.ae.

Breast Cancer Research and Treatment
|July 8, 2026
PubMed
Abstract

Insights

The SERENA-6 trial shows adapting breast cancer therapy based on cell-free DNA (cfDNA) molecular changes improves outcomes. This challenges relying solely on imaging for treatment decisions, paving the way for precision oncology.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Clinical Trial Design

Background:

  • Traditional oncology relies on radiologic progression for treatment changes.
  • Real-time molecular monitoring offers a new paradigm for cancer care.
  • The SERENA-6 trial investigated adapting therapy based on cell-free DNA (ctDNA) detected molecular progression.

Purpose of the Study:

  • To examine the clinical, scientific, and regulatory implications of ctDNA-guided treatment adaptation.
  • To evaluate molecularly adaptive trial designs in advanced breast cancer.
  • To discuss the integration of molecular biomarkers into treatment decision-making.

Main Methods:

  • Review of ODAC deliberations, regulatory discussions, and published data.
  • Analysis of expert perspectives on the SERENA-6 trial.
  • Examination of ctDNA-guided treatment adaptation strategies.

Main Results:

  • SERENA-6 demonstrated improved progression-free survival and quality of life.
  • Significant disease control was achieved with ctDNA-guided therapy adaptation.
  • Considerations for optimal timing and evidence for molecularly guided switching remain.

Conclusions:

  • Oncology is shifting towards biologically driven treatment strategies.
  • New frameworks are needed to define actionable molecular alterations.
  • SERENA-6 provides lessons for adaptive precision oncology trials beyond breast cancer.
Keywords:
Breast cancerCamizestrantESR1 mutationSERDctDNA

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...